Clinical risk factors used by cooperative groups to predict risk of disease recurrence in patients with early-stage HL
| EORTC/LYSA/FIL . | NCIC CTG . | GHSG . |
|---|---|---|
| Age >50 y | Age >40 y | E lesions |
| >3 Nodal areas | LD/MC | LMM |
| Bulky mediastinal >0.35 MTD | >3 Nodal areas | >2 Regions |
| ESR <50 mm/h (B Sx <30) | ESR >50 mm/h | ESR >50mm/h |
| EORTC/LYSA/FIL . | NCIC CTG . | GHSG . |
|---|---|---|
| Age >50 y | Age >40 y | E lesions |
| >3 Nodal areas | LD/MC | LMM |
| Bulky mediastinal >0.35 MTD | >3 Nodal areas | >2 Regions |
| ESR <50 mm/h (B Sx <30) | ESR >50 mm/h | ESR >50mm/h |
Presence of any of the risk factors indicates early unfavorable HL.
B Sx, B symptoms; E, extranodal extension; EORTC/LYSA/FIL, European Organization for Research and Treatment of Cancer/Lymphoma Study Association/Italian Lymphoma Foundation; ESR, erythrocyte sedimentation rate; GHSG, German Hodgkin Study Group; LD, lymphocyte depleted; LMM, large mediastinal mass; MC, mixed cellularity; MTD, maximum thoracic diameter on an anteroposterior chest radiograph; NCIC CTG, National Cancer Institute of Canada Clinical Trials Group; RCT, randomized controlled trial.